

Ji Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1021754/publications.pdf>

Version: 2024-02-01

92
papers

2,850
citations

201385

27
h-index

189595

50
g-index

94
all docs

94
docs citations

94
times ranked

4464
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a novel classification scheme for combining pathological T stage and log odds of positive lymph nodes for colon cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 228-236.	0.5	4
2	The role of nutritional assessment for predicting radiotherapy-induced adverse events in patients with gastric cancer. <i>British Journal of Radiology</i> , 2022, 95, 20201004.	1.0	9
3	A two-step method to improve image quality of CBCT with phantom-based supervised and patient-based unsupervised learning strategies. <i>Physics in Medicine and Biology</i> , 2022, 67, 084001.	1.6	11
4	Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study. <i>Clinical Cancer Research</i> , 2021, 27, 1329-1340.	3.2	82
5	Association Between Three-Dimensional Transrectal Ultrasound Findings and Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: An Observational Study. <i>Frontiers in Oncology</i> , 2021, 11, 648839.	1.3	3
6	An atlas-guided automatic planning approach for rectal cancer intensity-modulated radiotherapy. <i>Physics in Medicine and Biology</i> , 2021, 66, 155011.	1.6	2
7	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003741.	3.9	60
8	Screening and validation of a novel T stage-lymph node ratio classification for operable colon cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1513-1513.	0.7	4
9	Prognostic Inflammatory Index Based on Preoperative Peripheral Blood for Predicting the Prognosis of Colorectal Cancer Patients. <i>Cancers</i> , 2021, 13, 3.	1.7	12
10	Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. <i>Cell Stem Cell</i> , 2020, 26, 17-26.e6.	5.2	404
11	Prognostic Values of Preoperative Inflammatory and Nutritional Markers for Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 585083.	1.3	10
12	A Novel Prognostic Model Incorporating Carcinoembryonic Antigen in 3-Week or Longer Postoperative Period for Stage III Colon Cancer: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 566784.	1.3	5
13	Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by <i>UGT1A1</i> Status in Patients With Locally Advanced Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4231-4239.	0.8	61
14	The Gut Microbiome Is Associated With Therapeutic Responses and Toxicities of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients—A Pilot Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 562463.	1.8	34
15	The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, e58-e69.	1.0	15
16	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2020, 8, 1634-1634.	0.7	3
17	Knockdown Of TRIM31 Enhances Colorectal Cancer Radiosensitivity By Inducing DNA Damage And Activating Apoptosis. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8179-8188.	1.0	8
18	Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 3425-3434.	0.8	9

#	ARTICLE	IF	CITATIONS
19	<p>A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis</p>. Cancer Management and Research, 2019, Volume 11, 4153-4170.	0.9	2
20	An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985229.	1.4	8
21	Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer, 2019, 19, 606.	1.1	23
22	Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients. Cancer Medicine, 2019, 8, 3411-3419.	1.3	25
23	Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated With Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study. Journal of Cancer, 2019, 10, 1307-1312.	1.2	4
24	ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial. BMC Cancer, 2019, 19, 1117.	1.1	4
25	Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002). Radiation Oncology, 2019, 14, 215.	1.2	10
26	A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).. Journal of Clinical Oncology, 2019, 37, 3510-3510.	0.8	8
27	ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with â€˜watch and waitâ€™ approach.. Journal of Clinical Oncology, 2019, 37, 3544-3544.	0.8	4
28	Watch and wait approach following neoadjuvant chemoradiotherapy for rectal cancer patients: A single-centre experience.. Journal of Clinical Oncology, 2019, 37, 681-681.	0.8	0
29	GRECCAR2 trial: details worthy of more attention. Lancet, The, 2018, 391, 122.	6.3	1
30	Use of olaparib in patients with advanced gastric cancer. Lancet Oncology, The, 2018, 19, e75.	5.1	3
31	Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2018, 129, 143-148.	0.3	12
32	Reevaluation of laparoscopic surgery's value in pathological T4 colon cancer with comparison to open surgery: A retrospective and propensity score-matched study. International Journal of Surgery, 2018, 53, 12-17.	1.1	6
33	T3 subclassification using the EMD/mesorectum ratio predicts neoadjuvant chemoradiation outcome in T3 rectal cancer patients. British Journal of Radiology, 2018, 91, 20170617.	1.0	6
34	The HELOISE Study: Concerns About Trial Design. Journal of Clinical Oncology, 2018, 36, 302-302.	0.8	4
35	Evaluating the Effect of Lymph Node Status on Survival in Large Colon Cancer. Frontiers in Oncology, 2018, 8, 602.	1.3	3
36	Poorer prognosis in young female patients with non-metastatic colorectal cancer: a hospital-based analysis of 5,047 patients in China. Cancer Management and Research, 2018, Volume 10, 653-661.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 548-556.	0.3	42
38	Adjuvant therapy in resectable gastric cancer—the CRITICS trial. <i>Lancet Oncology</i> , The, 2018, 19, e330.	5.1	7
39	Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: a population-based study. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1241-1249.	1.0	45
40	Aneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer. <i>Oncology Letters</i> , 2018, 16, 1863-1868.	0.8	4
41	Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3608-3608.	0.8	6
42	Whole brain radiotherapy for non-small cell lung cancer. <i>Lancet</i> , The, 2017, 389, 1395.	6.3	1
43	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1588-1595.	1.9	18
44	Pembrolizumab for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 2302-2304.	13.9	26
45	Short-course radiotherapy with delayed surgery for rectal cancer. <i>Lancet Oncology</i> , The, 2017, 18, e294.	5.1	1
46	Adjuvant chemotherapy for patients with ypT0-2N0-category after neoadjuvant chemoradiotherapy for rectal cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 864-868.	0.4	1
47	Prophylactic cranial irradiation in small-cell lung cancer. <i>Lancet Oncology</i> , The, 2017, 18, e368.	5.1	0
48	Problematic Landmark Analysis Has Led to a Problematic Conclusion. <i>Journal of Clinical Oncology</i> , 2017, 35, 1967-1968.	0.8	1
49	Is there a prognostic value of tumor location among Chinese patients with colorectal cancer?. <i>Oncotarget</i> , 2017, 8, 38682-38692.	0.8	21
50	Pelvic recurrence after definitive surgery for locally advanced rectal cancer: a retrospective investigation of implications for precision radiotherapy field design. <i>Oncotarget</i> , 2017, 8, 95973-95980.	0.8	0
51	Association between dietary nitrate and nitrite intake and site-specific cancer risk: evidence from observational studies. <i>Oncotarget</i> , 2016, 7, 56915-56932.	0.8	61
52	Prognostic risk factors in patients with bone metastasis from colorectal cancer. <i>Tumor Biology</i> , 2016, 37, 16127-16134.	0.8	20
53	Sex, Race, and Age Disparities in the Improvement of Survival for Gastrointestinal Cancer over Time. <i>Scientific Reports</i> , 2016, 6, 29655.	1.6	6
54	Radiosensitization of Human Colorectal Cancer Cells by MLN4924. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 527-534.	0.8	26

#	ARTICLE	IF	CITATIONS
55	Negative to positive lymph node ratio is a superior predictor than traditional lymph node status in stage III colorectal cancer. <i>Oncotarget</i> , 2016, 7, 72290-72299.	0.8	7
56	Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 69507-69517.	0.8	35
57	Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy. <i>Oncotarget</i> , 2016, 7, 1014-1028.	0.8	52
58	CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 589-597.	0.7	35
59	BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. <i>American Journal of Cancer Research</i> , 2016, 6, 1345-57.	1.4	7
60	TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. <i>Medicine (United States)</i> , 2015, 94, e1955.	0.4	9
61	Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy. <i>OncoTargets and Therapy</i> , 2015, 8, 2291.	1.0	8
62	CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer. <i>Radiation Oncology</i> , 2015, 10, 57.	1.2	21
63	Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation. <i>Oncotarget</i> , 2015, 6, 11714-11722.	0.8	8
64	Implications for determining the optimal treatment for locally advanced rectal cancer in elderly patients aged 75 years and older. <i>Oncotarget</i> , 2015, 6, 30377-30383.	0.8	13
65	YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer. <i>Oncotarget</i> , 2015, 6, 41056-41062.	0.8	8
66	CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. <i>Tumor Biology</i> , 2014, 35, 9683-9691.	0.8	28
67	Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study. <i>Radiation Oncology</i> , 2014, 9, 278.	1.2	28
68	Baseline neutrophil-lymphocyte ratio (≥ 2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. <i>Radiation Oncology</i> , 2014, 9, 295.	1.2	75
69	Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 19-26.	1.1	156
70	MicroRNA-223 Enhances Radiation Sensitivity of U87MG Cells In Vitro and In Vivo by Targeting Ataxia Telangiectasia Mutated. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 955-960.	0.4	27
71	Overactivated Neddylaton Pathway as a Therapeutic Target in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju083.	3.0	144
72	Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. <i>Radiation Oncology</i> , 2014, 9, 70.	1.2	58

#	ARTICLE	IF	CITATIONS
73	A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. <i>Radiation Oncology</i> , 2013, 8, 130.	1.2	36
74	Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. <i>Radiation Oncology</i> , 2013, 8, 86.	1.2	38
75	Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. <i>Radiation Oncology</i> , 2013, 8, 10.	1.2	14
76	Electroacupuncture treatment for pancreatic cancer pain: A randomized controlled trial. <i>Pancreatology</i> , 2013, 13, 594-597.	0.5	55
77	Tumour diameter is a predictor of mesorectal and mesenteric lymph node metastases in anorectal melanoma. <i>Colorectal Disease</i> , 2013, 15, 1086-1092.	0.7	19
78	The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. <i>Future Oncology</i> , 2013, 9, 1489-1500.	1.1	17
79	Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation. <i>World Journal of Gastroenterology</i> , 2013, 19, 5520.	1.4	42
80	Impact of Lymph Node Ratio on the Survival of Patients with Hypopharyngeal Squamous Cell Carcinoma: A Population-Based Analysis. <i>PLoS ONE</i> , 2013, 8, e56613.	1.1	36
81	Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>PLoS ONE</i> , 2013, 8, e54233.	1.1	4
82	Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 733-743.	1.1	31
83	Postoperative Radiotherapy Improved Survival of Poor Prognostic Squamous Cell Carcinoma Esophagus. <i>Annals of Thoracic Surgery</i> , 2010, 90, 435-442.	0.7	70
84	Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients. <i>Radiation Oncology</i> , 2010, 5, 118.	1.2	11
85	The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 480-486.	0.6	91
86	A Simple Scoring System Based on Clinical Features to Predict Locally Advanced Rectal Cancers. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 1299-1305.	0.9	5
87	Prognostic Significance of the Metastatic Lymph Node Ratio in Node-Positive Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 3118-3123.	0.7	65
88	Application of active breathing control in 3-dimensional conformal radiation therapy for hepatocellular carcinoma: The feasibility and benefit. <i>Radiotherapy and Oncology</i> , 2008, 87, 439-444.	0.3	37
89	Prediction of Treatment Outcome by CD44v6 After Total Mesorectal Excision in Locally Advanced Rectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 54-61.	1.0	25
90	Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 189-195.	0.4	140

#	ARTICLE	IF	CITATIONS
91	Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. International Journal of Radiation Oncology Biology Physics, 2006, 65, 426-434.	0.4	230
92	Prediction of Radiation Induced Liver Disease Using Artificial Neural Networks. Japanese Journal of Clinical Oncology, 2006, 36, 783-788.	0.6	12